ClinicalTrials.gg

Program

belantamab

Also written as “Belantamab”, “Belantamab SC” and “Belantamab IV”.

In GlaxoSmithKline's pipeline, B-cell maturation antigen binder. Its studies are mostly in Multiple Myeloma · Autoimmune Diseases, led by GlaxoSmithKline.

Furthest: phase 2, since Jan 27, 20233 company-led studies, 2 open or runningNext primary completion: Aug 5, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline32 open or runningphase 2since Jan 27, 2023Jan 27, 2023Aug 5, 2027phase 1 · NCT07742527
  • Named in GlaxoSmithKline’s own pipeline as belantamab GSK2857914, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 27, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT05714839 · 123 planned · United States, Argentina, Australia and more
  2. May 9, 2024Phase 1 study in Autoimmune DiseasesNCT06413511
  3. Jul 29, 2026Phase 1 study in Multiple MyelomaNCT07742527 · 22 planned

Ahead

  1. Aug 5, 2027Primary completion: phase 1 study in Multiple MyelomaNCT07742527
  2. Aug 3, 2028Primary completion: phase 2 study in Multiple MyelomaNCT05714839

TargetBeta

“B-cell maturation antigen binder”the company's pipeline, read by Claude · source

Other programs on TNFRSF17

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
belantamab mafodotinruleGlaxoSmithKlinephase 325
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 37
anitocabtagene autoleucelruleGilead Sciencesphase 36
equecabtagene autoleucelrulenanjing-iaso-biotechnology-co-ltdphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
Evarucabgene Autoleucelrulenexcella-incphase 32

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07742527Multiple Myeloma1Not yet recruitingAug 5, 202722
NCT06413511Autoimmune Diseases1WithdrawnJul 8, 20250
NCT05714839Multiple Myeloma · United States, Argentina, Australia and more2RecruitingAug 3, 2028123

How it is read

Names in the registry

  • “Belantamab”, 2 entries
  • “Belantamab SC”, 1 entry
  • “Belantamab IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.